Clinical Trials Browser

NCT03321643 2026-03-18

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Phase 1 Active not recruiting

24 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03418038 2026-03-18

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Phase 2 Recruiting

80 enrolled

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT07480850 2026-03-18

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

40 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07021989 2026-03-17

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Not yet recruiting

38 enrolled

Lymphoid

Hodgkin Disease

NCT05139017 2026-03-10

waveLINE-003

Phase 2/3 Recruiting

290 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05171647 2026-03-06

SUNMO

Phase 3 Active not recruiting

208 enrolled 12 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT05502250 2026-03-06

HOVON164HL

Phase 2 Active not recruiting

75 enrolled

Lymphoid

Hodgkin Disease

NCT07451652 2026-03-05

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

Phase 2 Recruiting

10 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06624085 2026-03-04

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Recruiting

50 enrolled

Lymphoid

Lymphoma

NCT04542824 2026-03-03

EPCORE™ NHL-3

Phase 1/2 Active not recruiting

78 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-03-03

EPCORE™ NHL-2

Phase 1/2 Active not recruiting

543 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT06508658 2026-03-03

EPCORE DLBCL-4

Phase 3 Recruiting

360 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06806033 2026-03-02

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

100 enrolled

Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse